Clinical Overview
Protriptyline is a tricyclic antidepressant with unique activating properties among TCAs, making it less sedating than other tricyclics. It has a very long half-life (54-198 hours) and is indicated for depression, particularly in patients who experience excessive sedation with other antidepressants. Its activating effects may be beneficial for patients with depression characterized by fatigue and hypersomnia.
Primary Clinical Applications
Protriptyline is indicated for the treatment of depression and may be particularly suitable for patients with depression accompanied by fatigue, hypersomnia, or psychomotor retardation. Its activating properties make it unique among tricyclics and potentially useful when sedating antidepressants are not appropriate.
Mechanism and Clinical Profile
Protriptyline blocks norepinephrine and serotonin reuptake like other tricyclics but has less antihistaminergic activity, resulting in reduced sedation. Its very long half-life allows for once-daily dosing but also increases the risk of drug accumulation and makes dose adjustments challenging.
Clinical Considerations
The activating properties of protriptyline make it unsuitable for bedtime dosing and may cause insomnia or agitation in some patients. Its very long half-life requires careful dose titration and monitoring for accumulation. Like other tricyclics, it has significant anticholinergic effects and cardiovascular risks, but may be better tolerated in patients who cannot tolerate the sedation of other TCAs.
Prescribing Information
Dosing & Administration
Depression – Adults:
- Initial: 15-40 mg daily in divided doses
- Range: 15-60 mg daily
- Maximum: 60 mg daily
- Maintenance: Usually 15-40 mg daily
Elderly:
- Initial: 5 mg three times daily
- Range: 15-20 mg daily
- Titrate very slowly due to long half-life
Administration:
- Give in morning or early afternoon to avoid insomnia
- May divide into 3-4 doses daily
- Take with food to reduce GI upset
- Monitor for accumulation due to long half-life
Indications
- Treatment of depression
- Particularly useful for depression with fatigue or hypersomnia
Contraindications
- Hypersensitivity to tricyclic antidepressants
- Use within 14 days of MAOI therapy
- Acute recovery period following myocardial infarction
- Concurrent use with linezolid or IV methylene blue
Warnings & Precautions
- Boxed Warning: Increased risk of suicidal thoughts and behavior in patients under 25 years
- Cardiovascular effects: Monitor ECG in patients with cardiac disease
- Activating effects: May cause insomnia, agitation, anxiety
- Very long half-life: Risk of accumulation, slow dose adjustments needed
- Anticholinergic effects: Dry mouth, constipation, urinary retention
- Seizure risk: May lower seizure threshold
Drug Interactions
- MAOIs: Contraindicated – risk of serotonin syndrome
- CNS depressants: Enhanced sedation (though protriptyline is less sedating)
- CYP2D6 inhibitors: Significantly increase protriptyline levels
- Anticholinergic drugs: Additive anticholinergic effects
- Type 1C antiarrhythmics: Additive cardiac effects
Adverse Reactions
Common:
- Dry mouth, constipation, blurred vision, urinary retention
- Tremor, nervousness, insomnia, agitation
Unique characteristics:
- Less sedation than other tricyclics
- More activating effects
- Very long half-life effects
Serious:
- Cardiac arrhythmias, seizures, severe anticholinergic toxicity
Special Populations
- Elderly: Increased sensitivity, start with very low doses
- Cardiac Disease: Requires careful monitoring due to cardiac effects
- Pregnancy: Category C – use only if benefits outweigh risks
- Long half-life: Requires patience with dose adjustments and monitoring for accumulation
Medical Disclaimer: This information is for educational purposes only and is not intended as medical advice. Always consult with qualified healthcare professionals before making any treatment decisions. Individual patient circumstances may vary significantly.
